EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment

M Taleb Albrijawi, Reda Alhajj iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0303597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von M Taleb Albrijawi und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1 Department of Computer Engineering, Istanbul Medipol University, Istanbul, Turkey. Hauptthemen laut MEDLINE: HIV Protease Inhibitors, Drug Design, HIV Protease, HIV-1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The battle against viral drug resistance highlights the need for innovative approaches to replace time-consuming and costly traditional methods. Deep generative models offer automation potential, especially in the fight against Human immunodeficiency virus (HIV), as they can synthesize diverse molecules effectively. In this paper, an application of an LSTM-based deep generative model named “LSTM-ProGen” is proposed to be tailored explicitly for the de novo design of drug candidate molecules that interact with a specific target protein (HIV-1 protease). LSTM-ProGen distinguishes itself by employing a long-short-term memory (LSTM) architecture, to generate novel molecules target specificity against the HIV-1 protease. Following a thorough training process involves fine-tuning LSTM-ProGen on a diverse range of compounds sourced from the ChEMBL database. The model was optimized to meet specific requirements, with multiple iterations to enhance its predictive capabilities and ensure it generates molecules that exhibit favorable target interactions. The training process encompasses an array of performance evaluation metrics, such as drug-likeness properties. Our evaluation includes extensive silico analysis using molecular docking and PCA-based visualization to explore the chemical space that the new molecules cover compared to those in the training set. These evaluations reveal that a subset of 12 de novo molecules generated by LSTM-ProGen exhibit a striking ability to interact with the target protein, rivaling or even surpassing the efficacy of native ligands. Extended versions with further refinement of LSTM-ProGen hold promise as versatile tools for designing efficacious and customized drug candidates tailored to specific targets, thus accelerating drug development and facilitating the discovery of new therapies for various diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV Protease InhibitorsDrug DesignHIV ProteaseHIV-1Acquired Immunodeficiency SyndromeHumansMolecular Docking Simulation

Substanzen

HIV Protease InhibitorsHIV Proteasep16 protease, Human immunodeficiency virus 1

Autor:innen und Institutionen

  • 1 Department of Computer Engineering, Istanbul Medipol University, Istanbul, Turkey.
  • 2 Department of Computer Science, University of Calgary, Alberta, Canada.
  • 3 Department of Health Informatics, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Reda Alhajj

Zitieren

APA

Albrijawi, M. T., & Alhajj, R. (2024). LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment. PLOS ONE. https://doi.org/10.1371/journal.pone.0303597

Vancouver

Albrijawi MT, Alhajj R. LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment. PLOS ONE. 2024. doi:10.1371/journal.pone.0303597

BibTeX
@article{Albrijawi2024,
  author = {Albrijawi, M Taleb and Alhajj, Reda},
  title = {LSTM-driven drug design using SELFIES for target-focused de novo generation of HIV-1 protease inhibitor candidates for AIDS treatment},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0303597}
}
Kostenlos starten →